ArticleNeurology2017
Urinary p75
Registry-linked trialAbstract read
In one paragraph
Article in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06491732 (Electrical Impedance Myography Via the Myolex mScan as an ALS Biomarker), which is not on this map. Cited by 66 papers.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Electrical Impedance Myography Via the Myolex mScan as an ALS Biomarker
Who cites it
66 citing papers in PubMed.
- Trial
- Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.JAMA neurology · 2022Trial
- Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study.Annals of clinical and translational neurology · 2021Trial
- Nerve growth factor receptor (NGFR): A key player in glioblastoma progression.Biochimica et biophysica acta. Reviews on cancer · 2026Review
- The Target ALS Global Natural History Study: Cross-platform proteomics to accelerate biofluid biomarker and drug target discovery in amyotrophic lateral sclerosis.medRxiv : the preprint server for health sciences · 2026Article
- A lifespan staging model of basal forebrain cholinergic vulnerability.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Taming the "death receptor": translating the first-in-class p75Journal of translational medicine · 2026Review
- Evaluation of triumeq treatment on a TDP-43 mouse model of amyotrophic Lateral sclerosis.Scientific reports · 2026Article
- Skeletal Muscle Biomarkers of Amyotrophic Lateral Sclerosis: A Large-Scale, Multi-Cohort Proteomic Study.Annals of neurology · 2026Article
- Early biomarkers for predicting sepsis-induced shock: insights from inflammatory pathways and immune response.Frontiers in pharmacology · 2026Review
- IsomiR Utility in Amyotrophic Lateral Sclerosis Prognostication.medRxiv : the preprint server for health sciences · 2025Article
- Identification and validation of a tear fluid-derived protein biomarker signature in patients with amyotrophic lateral sclerosis.Acta neuropathologica communications · 2025Article
- Review
- Qualification of a electrochemiluminescence assay for the detection of human urinary neurotrophin receptor p75.Bioanalysis · 2025Article
- Article
- Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study.Clinical drug investigation · 2025Article
- Excessive Urinary p75ecd is a Potential Indicator of Amyotrophic Lateral Sclerosis: An American Cohort Study.Current neuropharmacology · 2025Article
- Urinary P75: a promising biomarker for amyotrophic lateral sclerosis.BMJ neurology open · 2025Article
- Diagnostic potential of urinary CX3CL1 for amnestic mild cognitive impairment and Alzheimer's disease.Frontiers in aging neuroscience · 2025Article
- Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis.medRxiv : the preprint server for health sciences · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Stephanie R ShepheardFrom the Department of Human Physiology & Centre for Neuroscience (S.R.S., L.W., T.C., M.-L.R.), Department of Gastroenterology and Surgery, Flinders Medical Centre (P.G.D.), and Department of Human Physiology, Centre for Neuroscience (P.G.D.), Flinders University, Adelaide, South Australia; Department of Neurology (J.W., M.B.), Miller School of Medicine, University of Miami, FL; and Neurology Department and MND Clinic (D.S.), Flinders Medical Centre, Bedford Park, South Australia.
Joanne WuuFrom the Department of Human Physiology & Centre for Neuroscience (S.R.S., L.W., T.C., M.-L.R.), Department of Gastroenterology and Surgery, Flinders Medical Centre (P.G.D.), and Department of Human Physiology, Centre for Neuroscience (P.G.D.), Flinders University, Adelaide, South Australia; Department of Neurology (J.W., M.B.), Miller School of Medicine, University of Miami, FL; and Neurology Department and MND Clinic (D.S.), Flinders Medical Centre, Bedford Park, South Australia.
Michell CardosoFrom the Department of Human Physiology & Centre for Neuroscience (S.R.S., L.W., T.C., M.-L.R.), Department of Gastroenterology and Surgery, Flinders Medical Centre (P.G.D.), and Department of Human Physiology, Centre for Neuroscience (P.G.D.), Flinders University, Adelaide, South Australia; Department of Neurology (J.W., M.B.), Miller School of Medicine, University of Miami, FL; and Neurology Department and MND Clinic (D.S.), Flinders Medical Centre, Bedford Park, South Australia.
Luke WiklendtFrom the Department of Human Physiology & Centre for Neuroscience (S.R.S., L.W., T.C., M.-L.R.), Department of Gastroenterology and Surgery, Flinders Medical Centre (P.G.D.), and Department of Human Physiology, Centre for Neuroscience (P.G.D.), Flinders University, Adelaide, South Australia; Department of Neurology (J.W., M.B.), Miller School of Medicine, University of Miami, FL; and Neurology Department and MND Clinic (D.S.), Flinders Medical Centre, Bedford Park, South Australia.
Phil G DinningFrom the Department of Human Physiology & Centre for Neuroscience (S.R.S., L.W., T.C., M.-L.R.), Department of Gastroenterology and Surgery, Flinders Medical Centre (P.G.D.), and Department of Human Physiology, Centre for Neuroscience (P.G.D.), Flinders University, Adelaide, South Australia; Department of Neurology (J.W., M.B.), Miller School of Medicine, University of Miami, FL; and Neurology Department and MND Clinic (D.S.), Flinders Medical Centre, Bedford Park, South Australia.
Tim ChatawayFrom the Department of Human Physiology & Centre for Neuroscience (S.R.S., L.W., T.C., M.-L.R.), Department of Gastroenterology and Surgery, Flinders Medical Centre (P.G.D.), and Department of Human Physiology, Centre for Neuroscience (P.G.D.), Flinders University, Adelaide, South Australia; Department of Neurology (J.W., M.B.), Miller School of Medicine, University of Miami, FL; and Neurology Department and MND Clinic (D.S.), Flinders Medical Centre, Bedford Park, South Australia.
David SchultzFrom the Department of Human Physiology & Centre for Neuroscience (S.R.S., L.W., T.C., M.-L.R.), Department of Gastroenterology and Surgery, Flinders Medical Centre (P.G.D.), and Department of Human Physiology, Centre for Neuroscience (P.G.D.), Flinders University, Adelaide, South Australia; Department of Neurology (J.W., M.B.), Miller School of Medicine, University of Miami, FL; and Neurology Department and MND Clinic (D.S.), Flinders Medical Centre, Bedford Park, South Australia.
Michael BenatarFrom the Department of Human Physiology & Centre for Neuroscience (S.R.S., L.W., T.C., M.-L.R.), Department of Gastroenterology and Surgery, Flinders Medical Centre (P.G.D.), and Department of Human Physiology, Centre for Neuroscience (P.G.D.), Flinders University, Adelaide, South Australia; Department of Neurology (J.W., M.B.), Miller School of Medicine, University of Miami, FL; and Neurology Department and MND Clinic (D.S.), Flinders Medical Centre, Bedford Park, South Australia. Mary-louise.rogers@flinders.edu.au mbenatar@miami.edu.
Mary-Louise RogersFrom the Department of Human Physiology & Centre for Neuroscience (S.R.S., L.W., T.C., M.-L.R.), Department of Gastroenterology and Surgery, Flinders Medical Centre (P.G.D.), and Department of Human Physiology, Centre for Neuroscience (P.G.D.), Flinders University, Adelaide, South Australia; Department of Neurology (J.W., M.B.), Miller School of Medicine, University of Miami, FL; and Neurology Department and MND Clinic (D.S.), Flinders Medical Centre, Bedford Park, South Australia. Mary-louise.rogers@flinders.edu.au mbenatar@miami.edu.
Funding
Uncovering new genes and disease modifiers for ALS and related disordersU54NS092091 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Michael Benatar · 2014 to 2026
$19.8MNINDS NIH HHS U54 NS092091
Abstract
objectiveTo evaluate urinary neurotrophin receptor p75 extracellular domain (p75
methodsThe population in this study comprised 45 healthy controls and 54 people with ALS, 31 of whom were sampled longitudinally. Urinary p75
resultsConfirming our previous findings, p75
conclusionsThe assay for urinary p75
Indexed as
Amyotrophic Lateral SclerosisDisease ProgressionAdultAgedAged, 80 and overBiomarkersCohort StudiesCreatinineEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedNerve Tissue ProteinsProportional Hazards ModelsReceptors, Nerve Growth FactorBiomarkersCreatinineNerve Tissue ProteinsNGFR protein, humanReceptors, Nerve Growth Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT06491732ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.